The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Slow Response to Vancomycin or Vancomycin plus Rifampin in Methicillin-resistant Staphylococcus aureus Endocarditis

Donald P. Levine, MD; Barbara S. Fromm, MA; and B. Ramesh Reddy, MD
[+] Article, Author, and Disclosure Information

Requests for Reprints: Donald P. Levine, MD, Department of Medicine, Room 5Q-14, Detroit Receiving Hospital, 4201 St. Antoine, Detroit, MI 48201.

Current Author Addresses: Dr. Levine: Department of Medicine, Room 5Q-14, Detroit Receiving Hospital, 4201 St. Antoine, Detroit, MI 48201.

Ms. Fromm and Dr. Reddy: Cardiology, Harper Hospital, 3990 John Road, Detroit, MI 48201.

©1991 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1991;115(9):674-680. doi:10.7326/0003-4819-115-9-674
Text Size: A A A

Objective: To determine the median response time to therapy with vancomycin alone or with vancomycin plus rifampin in patients with methicillin-resistant Staphylococcus aureus (MRSA) endocarditis.

Design: Cohort analysis of a randomized study.

Setting: University medical center.

Patients: Forty-two consecutive patients with MRSA endocarditis were randomly assigned to receive either vancomycin (group I) or vancomycin plus rifampin (group II) for 28 days.

Measurements: Clinical signs and symptoms were recorded, and blood cultures were obtained daily to determine the duration of bacteremia.

Main Results: The median duration of bacteremia was 9 days (7 days for group I and 9 days for group II). The median duration of fever for all patients and for each treatment group was 7 days. Six patients failed therapy, including three patients who died 5, 6, and 9 days after therapy was started, respectively. The other three patients who failed therapy required valve surgery on days 2, 22, and 27, respectively. Although patients had sustained bacteremia, no unusual complications were seen in either treatment group, and most patients responded to continued antibiotic therapy.

Conclusions: Slow clinical response is common among patients with MRSA endocarditis who are treated with vancomycin or vancomycin plus rifampin. Nevertheless, few complications appear to be related solely to this sustained bacteremia.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.